Soft tissue sarcoma - historical

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main soft tissue sarcoma page for current regimens.

1 regimens on this page
1 variants on this page

Locally advanced or metastatic disease, combination regimens

Doxorubicin & Olaratumab

back to top


Study Years of enrollment Evidence Comparator Comparative Efficacy
Tap et al. 2016 (CP15-0806) 2010-2013 Randomized Phase 2 (E-RT-esc) Doxorubicin Superior OS
Tap et al. 2020 (ANNOUNCE) 2015-2018 Phase 3 (E-esc) Doxorubicin Did not meet primary endpoint of OS


Targeted therapy

21-day cycles

Supportive medications


  1. CP15-0806: Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. link to original article contains verified protocol link to PMC article PubMed NCT02451943